Search clinical trials for: Combination tenofovir-emtricitabine

Total 5690 results

Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; HIV Prevention Trials Network

Completed

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

HIV Infection

United States, Puerto Rico
Tigenix S.A.U.

Completed

Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial (LTE)

Complex Perianal Fistula

Spain
University of Alberta
Canadian Institutes of Health Research (CIHR); Gilead Sciences; Abbott

Completed

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (HAART)

Primary Biliary Cirrhosis

Canada
HIV Prevention Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Gilead Sciences and other collaborators

Completed

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

HIV

South Africa, Zimbabwe
Professor Francois Venter
University of Cape Town

Completed

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants (EpiTAF)

Tuberculosis | HIV-1-infection

South Africa
Hospital Clinic of Barcelona

Completed

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

HIV Infection

Spain
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Chiang Mai University

Completed

Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy (TARGET)

Hiv

Thailand
CAN Community Health

Recruiting

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP) (Prep-RN)

Pre-Exposure Prophylaxis (PrEP) | Hiv Prevention

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (PEARLS)

HIV Infections

United States, Brazil, Peru, India, Malawi, Haiti, South Africa, Thailand, Zimbabwe
Centers for Disease Control and Prevention
Gilead Sciences; Botswana Ministry of Health

Completed

Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2)

HIV Infections

United States, Botswana
PENTA Foundation
Radboud University Medical Center; Baylor College of Medicine; Clinton Health... and other collaborators

Not yet recruiting

UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (UNIVERSAL1)

HIV Infection
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC

Recruiting

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

Lipid Metabolism Disorders | Cardiovascular Risk Factor | HIV I Infection

United States
Merck Sharp & Dohme LLC

Completed

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) (COVER)

HIV Infections
Gilead Sciences

Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada (SWIFT)

HIV Infection

United States, Puerto Rico, Canada
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
Sheba Medical Center

Terminated

Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera (DeepSwitch)

HIV

Israel
Hospital de Olhos Sadalla Amin Ghanem

Completed

Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia

Pterygium | Primary

Brazil
National Institute of Allergy and Infectious Diseases...
Bill and Melinda Gates Foundation

Completed

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men (iPrEx)

HIV Infections

United States, Brazil, Ecuador, Peru, South Africa, Thailand
MRC/UVRI and LSHTM Uganda Research Unit

Unknown

HIV PrEP Priming of Immune Effectors (PREPPIE)

HIV-1 Infections

Uganda
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

HIV Infections
University of Washington
Bill and Melinda Gates Foundation

Active, not recruiting

A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women (INSIGHT)

HIV Infections

Kenya, Malawi, South Africa, Swaziland, Uganda, Zambia, Zimbabwe
Saint Michael's Medical Center

Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

HIV Infection | Hepatitis C Infection

United States
University of Alabama at Birmingham
Bristol-Myers Squibb

Completed

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

Healthy

United States
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute of Mental Health...

Completed

Pre-Exposure Prophylaxis in YMSM

HIV

United States
Kirby Institute

Completed

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

HIV Infections

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084

HIV Infections

Zimbabwe, South Africa, Uganda
Columbia University
National Institute of Mental Health (NIMH); Impact Research & Development Organization

Completed

IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya

HIV

Kenya
St Stephens Aids Trust
Mylan Inc.

Completed

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

HIV

United Kingdom
University of Washington

Completed

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

HIV

United States
LVCT Health
London School of Hygiene and Tropical Medicine; Imperial College London; Bill... and other collaborators

Unknown

Introducing PrEP Into HIV Combination Prevention - Kenya (IPCP-Kenya)

HIV

Kenya
Mahidol University

Completed

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (STEREOS)

Dyslipidemias | HIV-1-infection | Sustained Virologic Response | Anti-Retroviral Agents | Efavirenz | Rilpivirine
Kirby Institute

Completed

Expanded PrEP Implementation in Communities in NSW (EPIC-NSW)

HIV | STI

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083

HIV Infections

United States
CONRAD

Completed

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

HIV

United States
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa
Indiana University

Completed

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

Pre-Exposure Prophylaxis

United States
Brigham and Women's Hospital
Gilead Sciences; The Fenway Institute

Active, not recruiting

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) (PrEPSteps)

HIV Infections | Substance Use Disorders

United States
Gilead Sciences

Completed

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

Chronic Hepatitis B

United States
Massachusetts General Hospital

Recruiting

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Diabetes Mellitus | Type 1 Diabetes | Diabetes type1 | Autoimmune Diabetes

United States
Brigham and Women's Hospital
Gilead Sciences

Completed

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use (DigiPrEP)

HIV/AIDS | Adherence, Medication | Substance Use Disorders

United States
University of Washington
Bill and Melinda Gates Foundation

Completed

PrEP in Breastfeeding Study

HIV Pre-exposure Prophylaxis During Breastfeeding

Kenya, Uganda
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaborators

Completed

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

HIV Infection

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

HIV-1 Infection

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
Fundacion IDEAA
ViiV Healthcare

Completed

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test (D2ARLING)

Hiv | HIV-1-infection

Argentina
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

HIV Infection | Hepatitis C

United States
Indiana University
Merck Sharp & Dohme LLC

Completed

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

HIV

United States

Search clinical trials for: Combination tenofovir-emtricitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations